Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia
about
sameAs
A comprehensive review on metabolic syndromeThe pivotal role of cholesterol absorption inhibitors in the management of dyslipidemiaTreatment of dyslipidemia with lovastatin and ezetimibe in an adolescent with cholesterol ester storage disease.Optimizing Treatment of Familial Hypercholesterolemia in Children and AdolescentsFenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a reviewIdentification of novel inhibitors of dietary lipid absorption using zebrafishThe target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1)The metabolic syndromeOpposing Gatekeepers of Apical Sterol Transport: Niemann-Pick C1-Like 1 (NPC1L1) and ATP-Binding Cassette Transporters G5 and G8 (ABCG5/ABCG8)Ezetimibe (Zetia): a new type of lipid-lowering agent.Influence of previous statin therapy on cholesterol-lowering effect of ezetimibe.Ezetimibe effectively reduces plasma plant sterols in patients with sitosterolemiaEzetimibe: a novel cholesterol-lowering agent that highlights novel physiologic pathways.Ezetimibe/simvastatin vs simvastatin in coronary heart disease patients with or without diabetes.Dyslipidemia in HIV-positive patients: a randomized, controlled, prospective study on ezetimibe+fenofibrate versus pravastatin monotherapy.Effects of ezetimibe on cholesterol metabolism in HIV-infected patients with protease inhibitor-associated dyslipidemia: a single-arm intervention trialEfficacy, safety and tolerability of ongoing statin plus ezetimibe versus doubling the ongoing statin dose in hypercholesterolemic Taiwanese patients: an open-label, randomized clinical trialCombination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemiaEffect of ezetimibe on incretin secretion in response to the intestinal absorption of a mixed meal.LDLR-Gene therapy for familial hypercholesterolaemia: problems, progress, and perspectivesHigh-dose simvastatin exhibits enhanced lipid-lowering effects relative to simvastatin/ezetimibe combination therapyFamilial hypercholesterolemia: current treatment and advances in management.Indices of cholesterol metabolism and relative responsiveness to ezetimibe and simvastatin.Effects of ezetimibe added to ongoing statin therapy on C-reactive protein levels in hypercholesterolemic patients.New lipid-modifying therapies.Ezetimibe restores biliary cholesterol excretion in mice expressing Niemann-Pick C1-Like 1 only in liverEzetimibe for management of hypercholesterolemia.Hepatic overexpression of abcb11 promotes hypercholesterolemia and obesity in mice.Ezetimibe: its novel effects on the prevention and the treatment of cholesterol gallstones and nonalcoholic Fatty liver diseaseNew drugs for the treatment of hypercholesterolaemia.Ezetimibe: a selective cholesterol absorption inhibitor.A randomized, double-blind, placebo-controlled study of the effect of ezetimibe on glucose metabolism in subjects with type 2 diabetes mellitus and hypercholesterolemia.Primary hypercholesterolemia: genetic causes and treatment of five monogenic disorders.Lipid lowering efficacy and safety of Ezetimibe combined with rosuvastatin compared with titrating rosuvastatin monotherapy in HIV-positive patients.High-density lipoprotein (HDL) cholesterol: leveraging practice-based biobank cohorts to characterize clinical and genetic predictors of treatment outcome.Modulation of lipid metabolism with the overexpression of NPC1L1 in mouse liver.Model-based development of gemcabene, a new lipid-altering agent.Premature cardiovascular disease in young women with heterozygous familial hypercholesterolemia.Combination of statin and ezetimibe for the treatment of dyslipidemias and the prevention of coronary artery disease.Mechanisms for cellular cholesterol transport: defects and human disease.
P2860
Q21284500-7EEE5F1B-A4CA-469E-BAD3-57A601AB6E0AQ24805607-7F840F67-B8A4-4368-90F0-360C2969BB14Q24812046-31E5799D-837E-4CAD-9504-4678C03C83A4Q26798119-182083A1-466C-42BD-82DF-AFB32EA11397Q28220294-34FF162C-E246-4C09-86CB-D866002CCF24Q28475286-734AB59B-91D8-415D-861C-6E930C5B7EB8Q28573173-6096AC45-99B2-4C67-8F48-8792106979B5Q33569142-93A30F9A-DADB-44DE-AAF0-3D278047D3C7Q33668002-12D48BED-CAE5-4EBD-90DE-4039D2BB9EA9Q33945373-22F65E6A-25A1-46E0-BCBC-02B24FA5AEB2Q33984025-33B844DB-D3DE-43AE-BB73-3E6C85565D18Q34049469-FC4F31AA-41F3-4D69-A2A4-1C295BC8A6B8Q34049540-C271669B-F7F5-46F1-B226-8936BE3A2FFBQ34053876-6EA6AADC-0AF8-4492-8AB8-B280BCBC5949Q34079102-B6B4B5EB-6F43-4733-9A07-3574F14CD235Q34217293-A30E7420-83EC-446D-A6E2-4AA02783ED84Q34279028-F904D88B-7114-4D51-9118-E028BE22AC42Q34334828-5A5DB71D-F80E-47CE-93EA-2A6AC3DF9887Q34357416-2D70A998-C343-4C79-BA34-7C9E100E7636Q34467839-6B1D5D59-774B-4527-9352-EAF3E8118223Q34729515-556213F8-85A9-4362-9849-C3042B433C71Q34769059-9A2DCC7F-F63B-4BE6-8A8F-7B5D0B66CA81Q34812315-4D91BC7B-7C87-4354-820E-09A862DA7A15Q35048374-2D9C9B43-F1D1-44FE-A123-D99CC6D0B610Q35073322-72AA656A-1652-4D31-845F-D390F7CBEBFCQ35119043-8FEFF1C7-FD48-441B-B4F3-D2485F1C1259Q35139242-69591302-1ED4-4950-9FCC-EA9C4ADDA2AEQ35269224-E87D5323-074E-456F-B541-FF127CB404A4Q35550630-471ECB87-F32F-40A4-8CCB-6DBEBA53AD8CQ35570944-4D91C385-6730-4846-93F4-55BE94A518D7Q35585225-37B389FD-9A95-4FD5-B371-E8D9F4A3605EQ35669490-D73B7A96-2ED4-4DE2-A00F-734CFB130214Q35696516-8A77F48F-5FD5-4B60-A533-E769DB185029Q35807156-5C2C44A6-AD3E-4BC8-9F2D-D54E1F6D8412Q35844499-ADD2E66F-AD8E-4AAC-88B9-B96A6FD22708Q36302709-6FC917EA-7D4F-4DB2-95A2-40ACDE4DDDBCQ36341650-C9526E43-F01A-41B0-8640-BA7B0DC80714Q36484907-01103849-249B-4C6F-96C8-4017EB1B206BQ36587621-E04264CB-6DAD-4C0C-A0E8-5AD8CEBB1ACAQ36610465-21845D70-D9AC-4343-B3AD-C9A35029FF96
P2860
Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia
description
2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2002
@ast
im November 2002 veröffentlichter wissenschaftlicher Artikel
@de
scientific article (publication date: 15 November 2002)
@en
vedecký článok (publikovaný 2002/11/15)
@sk
vědecký článek publikovaný v roce 2002
@cs
wetenschappelijk artikel (gepubliceerd op 2002/11/15)
@nl
наукова стаття, опублікована в листопаді 2002
@uk
مقالة علمية (نشرت في 15-11-2002)
@ar
name
Efficacy and safety of a poten ...... h primary hypercholesterolemia
@ast
Efficacy and safety of a poten ...... h primary hypercholesterolemia
@en
Efficacy and safety of a poten ...... h primary hypercholesterolemia
@nl
type
label
Efficacy and safety of a poten ...... h primary hypercholesterolemia
@ast
Efficacy and safety of a poten ...... h primary hypercholesterolemia
@en
Efficacy and safety of a poten ...... h primary hypercholesterolemia
@nl
prefLabel
Efficacy and safety of a poten ...... h primary hypercholesterolemia
@ast
Efficacy and safety of a poten ...... h primary hypercholesterolemia
@en
Efficacy and safety of a poten ...... h primary hypercholesterolemia
@nl
P2093
P1476
Efficacy and safety of a poten ...... h primary hypercholesterolemia
@en
P2093
Alexandre P LeBeaut
Carlos A Dujovne
Enrico P Veltri
J Frederick McNeer
Leslie J Lipka
Mark P Ettinger
Ramachandran Suresh
P304
P356
10.1016/S0002-9149(02)02798-4
P407
P577
2002-11-15T00:00:00Z